In July 2021, NovelCath’s parent company, Cirtec Medical, acquired Cardea Catheter Innovations, a vertically integrated manufacturer of minimally invasive catheter devices and complex delivery systems based in San Jose, CA. Cardea will integrate within the NovelCath brand, contributing to Cirtec’s Interventional segment focusing on structural heart, electrophysiology, and neurovascular applications.
NovelCath is contract manufacturer of highly engineered catheter delivery systems with locations in Minneapolis, MN and San Jose, CA. We specialize in the design, development and manufacturing of minimally invasive interventional delivery systems ranging from Structural Heart to Electrophysiology and Neurovascular applications. Our team is led by well known and trusted industry veterans with over 70 years of combined industry experience at solving complex steerable and multi-directional catheter shaft designs.
We recently expanded our Minneapolis, MN facility to include Nitinol processing. Our 20,000 square foot vertically integrated facility includes clean room assembly with dedicated prototyping lines, catheter assembly, extrusion, braiding, coiling and multiple reflow technologies.
NovelCath’s R&D team focus on supporting customer early stage development programs with design consultation, quick turn prototyping for concept verification to supporting animal studies, while always recognizing the long term manufacturability requirements.